Research Papers:

Genetic polymorphisms in leptin, adiponectin and their receptors affect risk and aggressiveness of prostate cancer: evidence from a meta-analysis and pooled-review

Meng-Bo Hu, Hua Xu, Ji-Meng Hu, Wen-Hui Zhu, Tian Yang, Hao-Wen Jiang _ and Qiang Ding

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:81049-81061. https://doi.org/10.18632/oncotarget.12747

Metrics: PDF 2045 views  |   HTML 2488 views  |   ?  


Meng-Bo Hu1,*, Hua Xu1,*, Ji-Meng Hu1, Wen-Hui Zhu1, Tian Yang, Hao-Wen Jiang1, Qiang Ding1

1Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China

*These authors have contributed equally to this work

Correspondence to:

Hao-Wen Jiang, email: [email protected]

Qiang Ding, email: [email protected]

Keywords: leptin, adiponectin, prostate cancer, genetic polymorphism, meta-analysis

Received: July 15, 2016     Accepted: October 12, 2016     Published: October 19, 2016


Leptin and adiponectin signaling was associated with development and progression of various cancers. The present study aimed to clarify the role of genetic variants in leptin, adiponectin and their receptors in prostate cancer. After comprehensive search and manuscript scanning, a total of 49 genetic variants were enrolled and examined for their relations to cancer risk and aggressiveness. In the meta-analysis, LEP rs7799039 (allele contrast: OR 1.133, 95%CI 1.024-1.254), ADIPOQ rs2241766 (allele contrast: OR 1.201, 95%CI 1.015-1.422) and ADIPOR1 rs10920531 (allele contrast: OR 1.184, 95%CI 1.075-1.305) variants were identified to be correlated with increased risk of prostate cancer. On the contrary, LEPR rs1137101 (allele contrast: OR 0.843, 95%CI 0.730-0.973) and ADIPOR1 rs2232853 (allele contrast: OR 0.638, 95%CI 0.535-0.760) variants were associated with decreased risk of prostate cancer. From the pooled-review, we additionally recognized eight variants associated with cancer risk and another eight variants associated with cancer aggressiveness, respectively. These observations indicated important roles of leptin, adiponectin and their receptors in the development and progression of prostate cancer. The identified polymorphisms might assist in developing better risk-assessment tools, as well as generating novel targeted therapies, especially for obese cancer patients with impaired leptin and adiponectin signaling.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12747